Our Mission

 

Our Mission

The HPTN is dedicated to the discovery and development of new and innovative research strategies to reduce the acquisition and transmission of HIV.

 

about hptn image

 

The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. HPTN studies evaluate new HIV prevention interventions and strategies in populations and geographical regions that bear a disproportionate burden of infection. The HPTN is committed to the highest ethical standards for its clinical trials and recognizes the importance of community engagement in all phases of the research process.

The HPTN research agenda is focused primarily on the use of integrated strategies: use of antiretroviral drugs (antiretroviral therapy and pre-exposure prophylaxis), interventions for substance abuse, particularly injection drug use, and behavioral risk reduction interventions with structural interventions.

The HPTN was established in 2000, building on the work of the HIV Network for Prevention Trials (HIVNET). HPTN’s Leadership and Operations Center (LOC), is based at FHI 360, Durham, North Carolina. The Laboratory Center (LC) is at Johns Hopkins University, Baltimore, Maryland and the Statistical and Data Management Center (SDMC) is housed within the Statistical Center for HIV/AIDS Research and Prevention (SCHARP) at the Fred Hutchinson Cancer Research Center in Seattle, Washington. The HPTN Modelling Centre, part of the SDMC, is a collaboration between the Department of Infectious Diseases Epidemiology at Imperial College London and SCHARP.

HPTN receives funding from three NIH institutes: the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health and the National Institute on Drug Abuse.

 

Learn More:

HPTN Populations of Focus

HPTN Fact Sheet

The HPTN Leadership and Operations Center (LOC) – webinar

The HPTN Statistical and Data Management Center (SDMC) – webinar


Conversations with the HPTN

Dr. Brenda Gati Mirembe, HPTN 111 co-chair, is a senior Investigator for MU-JHU CARE LTD in Kampala, Uganda. She has more than 14 years of experience in primary HIV prevention among adolescent girls and women. Dr. Mirembe has supported several studies, including the safety of long-acting cabotegravir injection among adolescent girls (HPTN 084-01).

Brian Minalga is the deputy director of the Office of HIV/AIDS Network Coordination (HANC) based at the Fred Hutchinson Cancer Center in Seattle. HANC supports all aspects of clinical trial operations across the ACTG, HPTN, HVTN, and IMPAACT. Brian also directs the HANC Legacy Project, focusing on including underrepresented populations in HIV clinical trials.

Juliane Etima, HPTN 084 and HPTN 111 study team member, is director of psychosocial support services at the MU-JHU Research Collaboration in Kampala, Uganda. She has extensive experience in the provision of social, emotional, and educational support and innovations for empowerment and equity for children, youth, women, and their families affected by HIV/AIDS.

Dr. Nomhle Ndimande-Khoza is a social and behavioral scientist at Wits RHI in Johannesburg, South Africa, and a past HPTN International Scholar. She has more than 15 years of dedicated experience in HIV prevention among adolescent girls and young women. Dr.